Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2011-11-22
- Lead Sponsor
- Bamrasnaradura Infectious Diseases Institute
- Target Recruit Count
- 142
- Registration Number
- NCT00483054
- Locations
- 🇹🇭
Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand
A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2020-07-17
- Target Recruit Count
- 28
- Registration Number
- NCT00476424
- Locations
- 🇹🇭
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand
Mechanisms of Lipodystrophy in HIV-Infected Pateints
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT00457665
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV
- Conditions
- Interventions
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2018-10-12
- Target Recruit Count
- 54
- Registration Number
- NCT00442962
- Locations
- 🇺🇸
Ucsd, Avrc, San Diego, California, United States
🇺🇸Brigham and Women's Hospital, Division of Infectious Disease, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
- Conditions
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT00350272
- Locations
- 🇵🇷
Clinical Trial Site, San Juan, Puerto Rico
Antiretroviral Therapy for Advanced HIV Disease in South Africa
- Conditions
- Interventions
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2013-05-21
- Target Recruit Count
- 1771
- Registration Number
- NCT00342355
- Locations
- 🇿🇦
Mtubatuba SIckbay, Kwazulu-Natal, South Africa
🇿🇦Umtata Sickbay, Eastaern Cape, South Africa
🇿🇦South African Military Health Services (SAMHS), Centurion, South Africa
Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Target Recruit Count
- 99
- Registration Number
- NCT00314626
- Locations
- 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
🇪🇸Hospital Costa del Sol, Marbella, Málaga, Spain
🇪🇸Hospital de Mataró, Mataro, Barcelona, Spain
Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV
- Conditions
- Interventions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Target Recruit Count
- 675
- Registration Number
- NCT00307502
- Locations
- 🇪🇸
Hospital de Figueres, Figueras, Barcelona, Spain
🇪🇸Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain
🇪🇸Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- International Medical Center of Japan
- Target Recruit Count
- 71
- Registration Number
- NCT00280969
- Locations
- 🇯🇵
International Medical Center of Japan, Shinjuku, Tokyo, Japan
Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2021-11-09
- Target Recruit Count
- 75
- Registration Number
- NCT00260078
- Locations
- 🇺🇸
Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States
🇺🇸Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.